Troxerutin Zentiva - instructions for use, dose, side effects, contraindications

Pharmacodynamics:Semisynthetic bioflavonoid (derivative of routine) of the class of benzopyrans. Venotonizing, antihypertensive agent. Reduces permeability and brittleness capillaries, strengthens the vascular wall, improvesmicrocirculation, rendersanti-corrosive action. It participates in oxidation-reduction processes, has antioxidant activity. Increases the density of the vascular wall, reduces exudation of the liquid part of the plasma and diapedesis of blood cells in the tissue, reduces inflammation in the vascular wall, limiting adhesion to its surface of platelets. The use of troxerutin is possible both at the initial and late stages of treatment of chronic venous insufficiency, it is possible to use as one of the componentscomplex treatment. Troxseroutine reduces puffiness and a feeling of heaviness in the legs, reduces the intensity of pain and cramps, improves trophism of tissues. Troxseroutine alleviates the symptoms associated with hemorrhoids (pain, exudation, itching, bleeding).

Due to the effect on the permeability and resistance of the capillary walls troxerutin helps slow the progression of diabetic retinopathy. The effect of troxerutin on the rheological properties of the blood contributes to the prevention of the development of microtrombosis of the retinal vessels.

Pharmacokinetics:

After oral administration, the drug is absorbed from the gastrointestinal tract, the maximum concentration in the blood plasma (C_mOh) is achieved on average 2 hours after admission. Partially metabolized in the liver. It is excreted mainly through the intestine (up to 65-70%), a smaller part (up to 25%) is excreted unchanged by the kidneys. Half-life (T1 / 2) troxerutin is approximately 24 hours.

Indications:

- Chronic venous insufficiency;

- trophic disorders in chronic venous insufficiency (dermatitis, trophic ulcers);

- phlebeurysm;

- superficial thrombophlebitis, periphlebitis;

- postthrombotic syndrome;

- post-traumatic edema, hematomas;

- hemorrhoids;

- diabetic angiopathy, retinopathy.

Contraindications:

- Hypersensitivity to troxerutin and other components of the drug;

- peptic ulcer of the stomach and duodenum;

- chronic gastritis (in the phase of exacerbation);

- pregnancy (I trimester);

- the period of breastfeeding;

- children under 18 years of age (experience of use is limited).

Carefully:

In patients with chronic renal failure (long-term use).

Pregnancy and lactation:

The use of the drug TROKSEROTIN ZENTIVA during the first trimester of pregnancy is contraindicated. The possibility of using the drug during the II and III trimester of pregnancy is determined by the doctor and is possible only if the expected benefit of treatment for the mother exceeds the potential risk for the child.

Data on the penetration of troxerutin into breast milk are absent. Application of the drug TROKSEROTIN ZENTIVA during breastfeeding is contraindicated.

Dosing and Administration:

Inside. Capsules should be swallowed whole, with food, with plenty of liquid.

The drug TROKSEROTIN ZENTIVA is used according to the doctor's prescription.Usually, 1 capsule is administered 3 times a day; as maintenance therapy - 1 capsule 2 times a day.

The course of treatment is on average 3-4 weeks, the need for longer treatment is determined individually.

Side effects:

Troxerutin is very well tolerated, in rare cases, light unwanted reactions occur.

Immune system disorders: hypersensitivity reactions.

Impaired nervous system: headache.

Disorders from the gastrointestinal tract: irritation of the mucous membrane of the gastrointestinal tract, nausea.

Disturbances from the skin and subcutaneous tissues: skin rashes, itching.

Vascular disorders: "tides" of blood to the face.

Overdose:

Troxerutin has very low toxicity. In case of an overdose, the following symptoms may appear: agitation, nausea, headache and "tides" of blood to the face. In case of an overdose, patients should rinse the stomach, take Activated carbon (within an hour after admission), see a doctor and, if necessary, carry out symptomatic and supportive treatment.

Interaction:

With simultaneous application enhances the effect of ascorbic acid on the resistance and permeability of the vascular wall.

Special instructions:

The experience of using the drug TROKSEROTIN ZENTIV in children under the age of 18 is not enough.

In the treatment of superficial thrombophlebitis or deep vein thrombosis, the drug TROCSEROTIN ZEPTIVA does not exclude the need to prescribe anti-inflammatory and antithrombotic therapy.

Effect on the ability to drive transp. cf. and fur:

Reception of the drug TROKSEROTIN ZENTIVA has no effect on motor and mental reactions, does not interfere with the management of vehicles and work with mechanisms.

Form release / dosage:Capsules 300 mg.

Packaging:

10 capsules in a PVC / A blisterl. By 3. 6 or 9 blisters in a cardboard pack together with instructions for use.

Storage conditions:

At a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life:

3 years.

The drug should not be used after the expiry date indicated on the package.

Terms of leave from pharmacies:Without recipe

Registration number:П N015161 / 01

Date of registration:13.08.2008

The owner of the registration certificate:Zentiva c.s.Zentiva c.s. Czech Republic

Manufacturer: & nbsp

ZENTIVA, k.s. Czech Republic

Representation: & nbspZENTIVA ZENTIVA Czech Republic

Information update date: & nbsp24.10.2015

Illustrated instructions

Instructions

Troxerutin Zentiva (Troxerutin Zentiva)